Kornimate/medical-research-clean huggingface dataset:
"act" for parents of children with autism spectrum disorder

Conditions: Stress

Summary: the investigators will develop and pilot test an intervention called "act for parents" which aims to decrease stress and improve quality of life in parents of children \< 15 years who have a diagnosis of autism spectrum disorder. a small randomized trial testing phase will be conducted to gather initial data on the treatment feasibility and acceptability, detect treatment effects between groups (act for parents versus treatment as usual), and to refine the treatment design for a future clinical trial.

acceptance and commitment therapy (act) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. act has been successfully applied to parents with similar mental health presentations. using a randomized controlled study design, investigators seek to gather initial data on the treatment feasibility and acceptability, detect treatment effects in a cohort of parents who have a child (under the age of 15) with autism spectrum disorder.

Eligibility criteria:
inclusion criteria: * a parent with a child (under the age of 15) with a diagnosis of pervasive developmental disorder-nos, asperger's disorder or autistic disorder * child with asd diagnosed by a mental health or medical professional * must be comfortable speaking and reading and understanding english exclusion criteria: * inability to attend sessions in person on the specified date/time/location of the intervention sessions * unwillingness to be audio-taped should randomization into the experimental (act) group occur.

Keywords: group therapy parents autism quality of life
point-of-care computed tomography (ct) chronic rhinosinusitis study

Conditions: Chronic Rhinosinusitis

Summary: the purpose of this research study is to determine whether or not computed tomography (ct) scans performed on patients with symptoms of chronic rhinosinusitis (crs) but without any physical signs of the disease will (1) prove to be less expensive in the treatment and evaluation as compared to current practices, (2) avoid the use of unnecessary antibiotic prescriptions, and (3) provide a more efficient way to diagnose conditions in patients who have had crs ruled out as a cause. the investigators hypothesize that current guidelines, when applied to subjects with symptoms of crs in the absence of physical signs may be associated with (1) increased unnecessary prescription of antibiotics, (2) delay in further essential workup, and (3) increased overall health care costs.


Eligibility criteria:
inclusion criteria: * subjects actively meeting the symptomatic criteria for crs as defined by the taskforce on rhinosinusitis but with physical and endoscopic examination that is within normal limits exclusion criteria: * subjects who are pregnant * subjects with a diagnosis of immune suppression or suspicion of malignancy that may be affecting the nose/paranasal sinuses * subjects who have had prior sinus surgery or who have been previously treated with a \>3 week course of broad spectrum antibiotics for crs

Keywords: chronic rhinosinusitis chronic sinusitis crs
hifu for focal ablation of prostate tissue: an observational study

Conditions: Prostate Cancer

Summary: the sonablate hifu device was approved by the u.s.fda for prostate tissue ablation in october, 2015. the purpose of this observational research study is to investigate the localized treatment of prostate cancer using hifu through clinical data and health-related quality of life (hrqol) questionnaires.

this observational study will serve to collect data from medical record review and questionnaires before and after high intensity focused ultrasound (hifu) for focal ablation of prostate tissue. the subject will have already undergone or opted to receive the hifu procedure as part of standard of care in order to participate in this study.

Eligibility criteria:
inclusion criteria: 1. age 40 years to 85 years 2. subject has elected or already undergone hifu therapy as their standard of care treatment methodand declined alternative treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone therapy) 3. psa ≤ 20 4. prostate volume of ≤ 70 cc 5. ability to complete informed consent form exclusion criteria: 1. prior treatment for prostate cancer (with the exception of androgen deprivation therapy) 2. medical contraindication to follow-up mpmri or prostate biopsy 3. unable to tolerate general or regional anesthesia 4. positive bone scan (only if bone scan has been done or clinically indicated. bone scan does not need to be performed for study eligibility determination.)
latinas learning about density

Conditions: Breast Cancer

Summary: this study will examine behavioral and psychological outcomes of breast density notification using a 3-group randomized design comparing usual written notification to two educationally enhanced approaches.

this is a 3-group randomized clinical trial to compare usual care to two educationally enhanced approaches to breast density notification. usual care involves sending written notification along with the mammogram report; all women will receive usual care. in addition, some women will receive written educational materials about breast density, with or without interaction with a promotora (culturally congruent health educator). study outcomes include short and long term assessments of psychological (anxiety, knowledge) and behavioral (continued mammography screening, discussion with primary care provider) outcomes. the study also includes qualitative inquiry and a cost analysis.

Eligibility criteria:
inclusion criteria: * female * attending screening mammography at mountain park health center * speak english or spanish exclusion criteria: * male * current diagnosis of breast cancer

Keywords: mammography breast density hispanic
tchcct-zhong-xing-emergency-department ultrasound with iv contrast in acute flank pain

Conditions: Acute Flank Pain

Summary: to evaluate the efficiency of ultrasound with iv contrast and compare this with the computed tomography in acute flank pain patient at emergency department.

acute flank pain is a common chief complaint in emergency departments (ed), but it is a challenge for physicians in ed to accurately diagnose. it can cause variable diseases and is in many cases lethal (e.g. aortic dissection, ruptured aortic aneurysm, renal artery dissection, ruptured tumor, etc). the computed tomography scan with iv contrast is an ideal tool to diagnose due to its high sensitivity and specificity and is a golden standard examination. however, currently point-of-care ultrasound is routinely used as first-line technique. as this procedure is non-invasive and has no radiative effect, it is considered more logical, especially for those critical patients who are not able to move and perform the ct scan. furthermore, the iodine contrast of ct scan is known as renal toxicity and should be used with caution in patient with hyperthyroidism and allergy to the contrast. the radiation of ct scan would be harmful to the pregnant patient as well. iv contrast ultrasound is a novel technique nowadays and it is widely used in diagnosing breast, liver, renal and pancreatic tumors. the ultrasound contrast using air microbubbles could enhance the scanning quality and also has high sensitivity and specificity. in ed, ultrasound with contrast now could be applied to the abdominal trauma and pediatric injury. for those patients with poor renal function, thyroid disease and pregnant women who cannot undergo iv contrast ct, iv contrast ultrasound provides a faster and safer way to evaluate patients in ed. we compared ct and ultrasound with iv contrast to determine the difference in efficiency between both examinations.

Eligibility criteria:
inclusion criteria: * acute flank pain who visit er exclusion criteria: * younger than 18 years old * known allergy to contrast

Keywords: acute flank pain ultrasound iv contrast
community outreach for palliative engagement -- parkinson disease

Conditions: Parkinson Disease Dementia; Parkinson Disease; Parkinson's Disease and Parkinsonism; Lewy Body Parkinsonism; Dementia With Lewy Bodies; Progressive Supranuclear Palsy; Corticobasal Degeneration; Multiple System Atrophy; Vascular Parkinsonism

Summary: the purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with parkinson's disease and lewy body dementia (lbd) or related conditions and their care partners. palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.

investigators propose to conduct a pragmatic stepped-wedge comparative effectiveness trial comparing a novel model of providing community-based palliative care for persons living with parkinson's disease (pd), lewy body dementia (lbd) and related disorders through online communities to usual care. our intervention includes support for both community neurologists (using the echo model of clinician support) as well as family caregivers and patients. investigators hypothesize that this model of care will improve patient quality of life and caregiver burden as well as other important secondary outcomes such as patient symptom burden and clinician burnout. this study will recruit neurology providers (md and apps) from 24 community neurology practices. these practices will identify participants for the study who have pd, lbd or a related condition and moderate to high palliative care needs. under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. after one year of baseline data collection, 6 practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. per the stepped-wedge design an additional six practices will be randomized 18 months into the data collection period, six at 24 months, and the final six will enter the intervention 30 months into the data collection period to allow for 12 months intervention recruitment for all practices.

Eligibility criteria:
inclusion criteria: patient inclusion criteria: • over age 40 years and diagnosed with pd or other causes of parkinsonism, such as progressive supranuclear palsy, multiple system atrophy and lewy body dementia by their community neurologist. exclusion criteria: patient exclusion criteria: * potential patient subjects who are unable or unwilling to commit to study procedures * presence of additional medical illnesses which requires palliative services (e.g. metastatic cancer) * already receiving palliative care or hospice services.
safety, tolerability and pharmacokinetics/pharmacodynamics (pk/pd) of shr-1603 in subjects with advanced malignancies

Conditions: Physiological Effects of Drugs; Neoplasms by Histologic Type; Lymphoma; Hematologic Neoplasms; Immunotherapy; Advanced Cancer

Summary: shr-1603-i-101 is an single-arm, open-label, dose finding phase i clinical trial of shr-1603 in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases. the study drug will be administered by intravenous infusion.

shr-1603-i-101 is a single-arm, open-label, dose finding, first-in-human(fih) clinical trial of shr-1603 intravenous infusion in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases. the primary objective of this study is to evaluate the safety and tolerability of shr-1603, as well as to determine the maximally tolerated dose(mtd) and define the recommended phase 2 dose(rp2d) of shr-1603. the study is consisted of a dose-escalation part 1 followed by a dose expansion part 2 and a clinical expansion part 3. part 1 will use accelerated titration and 3+3 dose-escalation design to determine mtd. part 2 will further evaluate the safety, tolerability and pk/pd features of shr-1603 based on the results of part 1. part 3 will include several cohorts of malignancies to collect preliminary efficacy information of shr-1603.

Eligibility criteria:
inclusion criteria: 1. ages 18 years or older; 2. eastern cooperative oncology group (ecog) performance status 0-1; 3. life expectancy no less than 12 weeks; 4. pathologically confirmed advanced solid tumor or relapsed/refractory lymphoma with measurable target lesions; 5. adequate bone marrow, haptic, renal and coagulation function. exclusion criteria: 1. evidence of central nervous system (cns) involvement; 2. previously treated with similar agents; 3. history of anticancer treatment within 4 weeks of enrollment (6 weeks for subjects treated with nitrosoureas or mitomycins); 4. anticipated to be involved in other anti-cancer treatments expect for palliative care during the trial; 5. history of anti-cancer vaccination; or history of vaccination using attenuated vaccines within 4 weeks of enrollment; 6. history of red blood cell (rbc) transfusion within or treatment with erythropoitin(epo) within 3 months of enrollment; 7. history of grade 3 or higher thrombolic incidence within 2 years of enrollment, or using antithrombotic/anticoagulant agents; 8. with confirmed immunodeficiency, uncontrolled auto-immune disease, uncontrolled cardiovascular disease, uncontrolled or active infection; 9. substance abuse.

Keywords: advanced solid tumor r/r lymphoma
outcomes of neoadjuvant therapy for rectal cancer in a tertiary asian institute

Conditions: Rectal Cancer; Oncology

Summary: this is a retrospective cohort study that aims to evaluate the correlation of magnetic resonance tumour regression grade (mrtrg) and pathological trg (ptrg) of locally advanced rectal cancer after neoadjuvant long course chemoradiotherapy as well as the prognostic value of mrtrg on survival.


Eligibility criteria:
inclusion criteria: * rectal cancer * at least 1 high risk feature on mri * undergo long course neoadjuvant chemoradiotherapy (lccrt) exclusion criteria: * metastatic disease * patients who undergo short course radiotherapy * patients without a repeat mri after completion of lccrt
the prospective collection, storage and reporting of data on patients undergoing hematopoietic stem cell transplantation utilizing a standard preparative regimen

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma; Germ Cell Neoplasms; Myelodysplastic Syndromes; Chronic Lymphocytic Leukemia; Immunodeficiency Diseases

Summary: to provide the irb approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.


Eligibility criteria:
inclusion criteria: planned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant exclusion criteria: participation in any other treatment research protocol
the site study - dexamethasone ophthalmic insert in or on day of surgery versus in-office post-op day 1

Conditions: Cataract

Summary: to assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (iol) compared to insertion 1-day post-op.

this is a randomized, controlled study to evaluate the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (iol) compared to insertion 1-day post-op. there will be approximately 50 eyes with two groups: group 1 (up to 10 eyes) will receive the insert in the lower punctum on the day of surgery in the or. group 2 (up to 40 eyes) will receive the insert in the lower punctum on the day after surgery in the hopd. each subject's participation is expected to last for approximately 1 month and will be required to complete five scheduled visits over the course of the study period: baseline (screening visit), operative visit/insertion day (day 0), day 1, day 7 and day 30.

Eligibility criteria:
inclusion criteria: * subjects will be eligible for study participation if they: 1. are an adult subject aged 65 years or older 2. are planning to undergo non-complicated cci ce/pciol in one or both eyes 3. are willing and able to comply with clinic visits and study related procedures 4. are willing and able to sign the informed consent form exclusion criteria: * subjects are not eligible for study participation if they: 1. have active infectious systemic disease 2. have active infectious ocular or extraocular disease 3. have unobstructed nasolacrimal duct in the study eye(s) 4. have known hypersensitivity to dexamethasone or are a known steroid responder 5. have a history of ocular inflammation or macular edema 6. are currently being treated with immunomodulating agents in the study eye(s) 7. are currently being treated with immunosuppressants and/or oral steroids 8. are currently being treated with corticosteroid implant (i.e. ozurdex) 9. have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye 10. have a history of complete punctal occlusion in one or both punctum 11. currently use topical ophthalmic steroid medications 12. are unwilling or unable to comply with the study protocol 13. are determined by the investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) or if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment
iv insulin protocol in diabetes and renal transplantation

Conditions: Kidney Transplantation; Diabetes; Hyperglycemia

Summary: purpose: the purpose of this study is to provide tight blood sugar control using insulin given through the veins at the time of kidney transplantation and up to 3 days after surgery. after release from the hospital, the patient will control blood sugar with subcutaneous insulin injections or pills. with this approach, outcomes should improve for diabetic transplant patients such as longer life of the new kidney, fewer hospital readmissions, decreased associated infections, and other advantages. hypothesis: it is hypothesized that intensive glycemic control will lead to better clinical and biochemical outcomes and improved long-term graft survival.

research design: a randomized control trial comparing intensive intravenous insulin (ivi) for use in the hospital followed by intensive subcutaneous (sc) insulin use for in-patient and out-patient glycemic control will be conducted.

Eligibility criteria:
inclusion criteria: * 18 years of age and greater, * diabetes diagnosis (type 1 and type 2, awaiting a living or cadaveric renal transplant, renal transplant candidates admitted to musc medical center for a donor kidney, fbg \>100 mg/dl per admission screening labs, random bg \>120mg/dl per admission screening labs, and * willing and able to provide informed consent exclusion criteria: * history of an active gi bleed in the previous 3 mos, * scheduled to receive a simultaneous pancreas transplant, * history of a functioning pancreatic transplant, * patient currently managed on an insulin pump, * unable or unwilling to provide informed consent, and * unable to commit to the study protocol including the outpatient follow-up phase of care

Keywords: kidney transplantation diabetes hyperglycemia
secondary interval cytoreductive surgery in platinum-sensitive recurrent epithelial ovarian cancer

Conditions: Recurrent Ovarian Carcinoma

Summary: about 80% of advanced ovarian cancer patients recurred in 2-3 years. secondary cytoreduction benefits selected patients who have high chance of complete resection. whether secondary interval surgery can be used at recurrence is not known.

our study aims to evaluate the complete resection rate at interval cytoreductive surgery for recurrent ovarian cancer patients, and to determine the safety and survival outcomes of this approach.

Eligibility criteria:
inclusion criteria: * histologically diagnosed eoc, fallopian tube or primary peritoneal carcinoma * \>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or parpi, at primary setting * platinum-free interval should be \>=6 months from the last dose of platinum-based chemotherapy * upfront scr not feasible * patients should have eastern cooperative oncology group (ecog) performance score 0 to 2 within 28 days prior to recruitment. * patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment. exclusion criteria: * non-epithelial or borderline tumors are excluded * patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded. * patients using more than one line of chemotherapy are excluded. * patients who have platinum-resistant or refractory recurrence are excluded. * patients having second relapse or beyond are excluded. * patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment
does atorvastatin prevent post operative atrial fibrillation after pulmonary resection: a randomized clinical study

Conditions: Arrhythmia

Summary: the purpose of this study is to determine if atorvastatin (lipitor) reduces the occurence of abnormal heart rhythm (atrial arrhythmia) following non cardiac thoracic surgery.

the incidence of atrial arrhythmia after thoracic, non-cardiac procedures is exceedingly common and has been reported to occur in between 10-39% of patients. it has been shown to increase majority morbidity and also delay hospital discharge. recent studies suggest that one week of pre-operative atorvastatin may reduce the incidence of post-operative atrial arrhythmia in patients who undergo cardiac surgery and a multi-institutional study is currently underway to further examine this concept. however, there are no published prospective randomized studies to date that have evaluated the effectiveness of atorvastatin to reduce atrial arrhythmia in patients who undergo thoracic, non-cardiac operations such as esophagectomy or pulmonary resection. the object of this study is to determine if atorvastatin reduces the incidence of atrial arrhythmia (atrial fibrillation or flutter) following non-cardiac thoracic surgery, specifically pulmonary resections.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective non-cardiac thoracic surgery requiring thoracotomy for resection exclusion criteria: * past medical history of pacemaker implantation * pregnancy or lactating * history of atrial arrhythmia within the past year * elevated liver enzymes pre-operatively * past medical history of any liver disease or history of liver transplantation * use of statins or any anti-arrhythmics (including beta-blockers, calcium channel blockers, digoxin) within 3 months prior to surgery * pre-op ekg showing atrial arrhythmia